Search research articles

Related Concept Videos

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Analysis Of The Treatment And Prognosis Of 266 Cases Of Extranodal Natural Killer/t-cell Lymphoma, Nasal Type In A Single Medical Center.

Home
Analysis Of The Treatment And Prognosis Of 266 Cases Of Extranodal Natural Killer/t-cell Lymphoma, Nasal Type In A Single Medical Center.

Related Experiment Video

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a

Lei Yang¹, Liqiang Wei¹, Xin Li¹

¹Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Frontiers in Oncology

|April 18, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Treatment strategies significantly impact extranodal NK/T-cell lymphoma, nasal type (ENKTL) prognosis. Achieving complete remission after treatment is a key factor for better survival in ENKTL patients.

Keywords:

asparaginase extranodal NK/T-cell lymphoma prognostic factors survival rates therapeutic outcomes

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue NALT in Mouse Responses to Vaccines

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue NALT in Mouse Responses to Vaccines

Published on: August 1, 2012

Related Experiment Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue NALT in Mouse Responses to Vaccines

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue NALT in Mouse Responses to Vaccines

Published on: August 1, 2012

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive non-Hodgkin lymphoma with variable clinical behavior.
Optimal treatment strategies and prognostic factors for ENKTL remain areas of active investigation.
Understanding these factors is crucial for improving patient outcomes.

Purpose of the Study:

To evaluate the influence of diverse treatment modalities on the prognosis of extranodal NK/T-cell lymphoma, nasal type (ENKTL).
To identify significant risk factors affecting survival rates in ENKTL patients.
To analyze treatment outcomes within a single medical center cohort.

Main Methods:

Retrospective analysis of clinical data from 266 ENKTL patients.

Stratification of treatment based on disease stage: sandwich therapy for Stages I/II, chemotherapy plus autologous stem cell transplantation for Stages III/IV.

Survival and prognosis assessed using Kaplan-Meier curves and Cox regression analyses.

Main Results:

Overall complete remission (CR) rate was 71.05%, with a 5-year progression-free survival (PFS) of 70.4% and overall survival (OS) of 70.9%.
Patients in Stage I/II showed significantly better outcomes (PFS 79.8%, OS 81.1%) compared to Stage III/IV (PFS 41.7%, OS 40.9%).
Achieving CR post-treatment emerged as an independent positive prognostic factor (P<0.001).

Conclusions:

Disease stage and achievement of complete remission are critical determinants of survival in ENKTL.
Early-stage ENKTL patients treated with sandwich therapy demonstrate favorable prognoses.
Further research into ENKTL pathogenesis and drug resistance mechanisms is warranted for improved therapeutic strategies.